The United Laboratories International Holdings Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ULIHF research report →
About the company
The United Laboratories International Holdings Limited functions as a pharmaceutical investment holding company, overseeing the entire spectrum of drug-related activities from initial research and development to manufacturing, distribution, and sales. Its business operations are structured into three main divisions: Bulk Medicine, Intermediate Products, and Finished Products. The company offers a diverse portfolio of medicinal products, including oral and injectable antibiotics, anti-cold and cough remedies, ophthalmic treatments, antiviral drugs, solutions for hepatitis B and diabetes, external dermatological preparations, cardiovascular, cerebrovascular, and nervous system medications, as well as vitamins.
- CEO
- Hoi Shan Tsoi
- IPO
- 2014
- Employees
- 17,000
- HQ
- Yuen Long, HK
Price Chart
- Market Cap
- $2.45B
- P/E
- 7.58
- P/S
- 1.21
- P/B
- 0.91
- EV/EBITDA
- 3.44
- Div Yield
- 6.08%
- Gross Margin
- 41.74%
- Op Margin
- 17.21%
- Net Margin
- 15.79%
- ROE
- 12.65%
- ROIC
- 8.15%
- Revenue
- $12.87B · -6.46%
- Net Income
- $2.03B · -23.60%
- EPS
- $1.05 · -28.08%
- Op Income
- $2.21B
- FCF YoY
- -35.63%
- 52W High
- $2.28
- 52W Low
- $1.18
- 50D MA
- $1.25
- 200D MA
- $1.65
- Beta
- 0.29
- Avg Volume
- 263
Get TickerSpark's AI analysis on ULIHF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ULIHF coverage
Recent articles, reports, and earnings notes.
No research on ULIHF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ULIHF report →Similar companies
Peers in the same neighborhood.